US investment bank states that hVIVO is reinforced by powerful industry momentum.

Stifel’s Insight on hVIVO PLC

The esteemed American investment bank, Stifel, has recently launched an analysis of hVIVO PLC – a leading contract research organisation (CRO) that focuses on human challenge clinical trials (HCTs). Stifel suggests a target share price of 27p, which is a notable 42% jump from hVIVO’s existing price of 19p.

Why the Optimism?

The optimistic projection is rooted in hVIVO’s persistent financial strength and its pivotal role in the pharma and biotech domains.

  • Unique Positioning: hVIVO stands out globally for its expertise in HCTs. These trials involve exposing healthy participants to infectious diseases in a strictly regulated setting. For pharmaceutical and biotech companies, this approach is cost-effective, swift, and strategically beneficial. Stifel’s insights hint at hVIVO being the top choice for enterprises because of its vast expertise in HCTs.
  • Financial Growth: In 2022 alone, hVIVO boasted a remarkable 30% YoY revenue surge and has a three-year CAGR at 51%. By June 30, 2023, its record contracted order book reached £78 million. This provides a clear view of its potential revenues up to late 2024. The firm’s EBITDA for 2022 stood at £9.1 million, translating to an 18.7% margin. For 2023, Stifel anticipates hVIVO’s revenue to touch £55 million with an EBITDA margin of 19%.
  • Revenue Diversification: hVIVO’s financial foundation is bolstered by two other entities – FluCamp, their volunteer enlistment platform, and Venn Life Sciences, their internal consultancy service. These arms not only supplement hVIVO’s growth but also position it to capitalize on cross-selling opportunities with HCT contracts.
  • The Market’s Future: The resurgence of interest in infectious diseases and the increasing appeal for HCTs predict a favourable trajectory for hVIVO. Their consistent performance, their growth in contract acquisitions, and plans for facility expansion underpin this confidence. Stifel’s note encapsulates the sentiment: the renewed focus on infectious diseases, coupled with hVIVO’s consistent performance metrics and expansion plans, makes a compelling investment proposition.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.